高级搜索
马蔺子素(Iq7611)的放射增敏作用[J]. 肿瘤防治研究, 1998, 25(1): 69-70.
引用本文: 马蔺子素(Iq7611)的放射增敏作用[J]. 肿瘤防治研究, 1998, 25(1): 69-70.
Radiosensitization of Iq7611[J]. Cancer Research on Prevention and Treatment, 1998, 25(1): 69-70.
Citation: Radiosensitization of Iq7611[J]. Cancer Research on Prevention and Treatment, 1998, 25(1): 69-70.

马蔺子素(Iq7611)的放射增敏作用

Radiosensitization of Iq7611

  • 摘要: 目的:观察马蔺子素在恶性肿瘤中的放射增敏和毒付作用。 方法:52例病人进行了放疗加口服马蔺子素的观察。 观察组口服lq7611120mg/次, 2次/日, 分别在放疗前后各2小时服用; 对照组不服药仅单纯放疗。 结果:按UICC实体瘤观察指标和WHO推荐的毒付反应分级标准,观察组的原发灶和转移灶近期缓解率好于对照组, 毒付作用未增加。 结论:该药有一定的增敏作用, 毒付作用可以耐受, 建议进一步扩大临床试用。

     

    Abstract: Purpose: To observe the radiosensitization and side-effects in the treatmentof malignant tumors. Materials and Metheds: From October, 1994 to February,1995, 52 pattens were treated with radiotherapy and Iq7611. In the observed group,Iq7611 was taken orally, 120mg a time, 2 times a day, 2 hours before and after radiotherapy. In the control group, the patients were treated with radiontherapy alone. Results: The instant result of primary and metastatic foci and the side-effects were classified according tO the observed items of UICC and the classification criteria of Poisonous and side effects recommended by WHO. The instant result was better in the Observed group than in the control group, but the Poisonous and side effects were nothigher. Conclusion: The results show that the Iq7611 has radiosensitization. The poisonous and side effects were well tolerated. The clinical study should be done further.

     

/

返回文章
返回